Potential value of mesenchymal stem cells and their derivatives in repairing donor liver
-
摘要: 近年来，我国器官移植工作发展迅速，器官供需比例严重失衡。为解决供肝短缺问题，修复扩大标准供肝、改善供肝质量是当前的重要研究方向。间充质干细胞是一类具有自我更新、分化潜能的干细胞，具有免疫调节和组织修复等功能，其衍生物具有低免疫原性和良好的生物相容性等优点，因而广泛应用于各种疾病的治疗。本文通过综述间充质干细胞及其外泌体和细胞外囊泡在改善肝脏脂肪变性、修复缺血-再灌注损伤、促进小体积供肝再生方面的相关研究进展，总结间充质干细胞及其衍生物在供肝修复应用中的可行性及安全性，为修复边缘供肝、改善供肝质量提供新思路。Abstract: In recent years, organ transplantation has developed rapidly in China, whereas the proportion of supply and demand of organs for donation is severely unbalanced. To resolve the shortage of donor livers, repairing extended criteria donor liver and improving the quality of donor liver are critical research directions. Mesenchymal stem cell (MSC) is a category of stem cells with self-renewal and differentiation potential, which possess the functions of immunomodulation and tissue repair. The derivatives of MSC have the advantages of low immunogenicity and high biocompatibility, which have been widely applied in the treatment of multiple diseases. In this article, research progress on the role of MSC, exosomes and extracellular vesicles in alleviating liver steatosis, repairing ischemia-reperfusion injury and promoting the regeneration of small-for-size liver allograft was reviewed, and the feasibility and safety of MSC and the derivatives in repairing donor liver were summarized, aiming provide novel ideas for repairing marginal donor liver and enhancing the quality of liver allograft.
-
[1] DE MAGNÉE C, BRUNÉE L, TAMBUCCI R, et al. Is ABO-incompatible living donor liver transplantation really a good alternative for pediatric recipients?[J]. Children (Basel), 2021, 8(7): 600. DOI: 10.3390/children8070600. [2] SCHOLD JD, KOVAL CE, WEE A, et al. Utilization and outcomes of deceased donor SARS-CoV-2-positive organs for solid organ transplantation in the United States[J]. Am J Transplant, 2022, 22(9): 2217-2227. DOI: 10.1111/ajt.17126. [3] NITTA S, KUSAKARI Y, YAMADA Y, et al. Conversion of mesenchymal stem cells into a canine hepatocyte-like cells by Foxa1 and Hnf4a[J]. Regen Ther, 2020, 14: 165-176. DOI: 10.1016/j.reth.2020.01.003. [4] LUAN Y, KONG X, FENG Y. Mesenchymal stem cells therapy for acute liver failure: recent advances and future perspectives[J]. Liver Res, 2021, 5(2): 53-61. [5] PEGTEL DM, GOULD SJ. Exosomes[J]. Annu Rev Biochem, 2019, 88: 487-514. DOI: 10.1146/annurev-biochem-013118-111902. [6] ClinicaiTrials. Gov[EB/OL]. [2023-02-14]. https://clinicaltrials.gov/ .[7] DU X, LI H, HAN X, et al. Mesenchymal stem cells-derived exosomal miR-24-3p ameliorates non-alcohol fatty liver disease by targeting Keap-1[J]. Biochem Biophys Res Commun, 2022, 637: 331-340. DOI: 10.1016/j.bbrc.2022.11.012 [8] CHENG L, YU P, LI F, et al. Human umbilical cord-derived mesenchymal stem cell-exosomal miR-627-5p ameliorates non-alcoholic fatty liver disease by repressing FTO expression[J]. Hum Cell, 2021, 34(6): 1697-1708. DOI: 10.1007/s13577-021-00593-1. [9] KANG Y, SONG Y, LUO Y, et al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate experimental non-alcoholic steatohepatitis via Nrf2/NQO-1 pathway[J]. Free Radic Biol Med, 2022, 192: 25-36. DOI: 10.1016/j.freeradbiomed.2022.08.037. [10] WU R, FAN X, WANG Y, et al. Mesenchymal stem cell-derived extracellular vesicles in liver immunity and therapy[J]. Front Immunol, 2022, 13: 833878. DOI: 10.3389/fimmu.2022.833878. [11] BI Y, GUO X, ZHANG M, et al. Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice[J]. Stem Cell Res Ther, 2021, 12(1): 602. DOI: 10.1186/s13287-021-02663-5. [12] YANG Z, XIA Q, LU D, et al. Human mesenchymal stem cells treatment improved hepatic lesions and reversed gut microbiome disorder in non-alcoholic steatohepatitis[J]. Aging (Albany NY), 2020, 12(21): 21660-21673. DOI: 10.18632/aging.103962. [13] EL-DERANY MO, ABDELHAMID SG. Upregulation of miR-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: emphasis on caspase-2 signaling inhibition[J]. Biochem Pharmacol, 2021, 190: 114624. DOI: 10.1016/j.bcp.2021.114624. [14] WAN YM, LI ZQ, LIU C, et al. Mesenchymal stem cells reduce alcoholic hepatitis in mice via suppression of hepatic neutrophil and macrophage infiltration, and of oxidative stress[J]. PLoS One, 2020, 15(2): e0228889. DOI: 10.1371/journal.pone.0228889. [15] SAKAI Y, FUKUNISHI S, TAKAMURA M, et al. Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy[J]. Regen Ther, 2021, 18: 97-101. DOI: 10.1016/j.reth.2021.04.003. [16] LIU Y, DONG Y, WU X, et al. The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials[J]. Stem Cell Res Ther, 2022, 13(1): 204. DOI: 10.1186/s13287-022-02882-4. [17] SHI M, LI YY, XU RN, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial[J]. Hepatol Int, 2021, 15(6): 1431-1441. DOI: 10.1007/s12072-021-10199-2. [18] FERNÁNDEZ AR, SÁNCHEZ-TARJUELO R, CRAVEDI P, et al. Review: ischemia reperfusion injury-a translational perspective in organ transplantation[J]. Int J Mol Sci, 2020, 21(22): 8549. DOI: 10.3390/ijms21228549. [19] 高伟东, 杨龙龙, 尹清臣. 氧化应激反应在边缘供肝肝移植缺血-再灌注损伤中的作用研究进展[J]. 器官移植, 2022, 13(1): 126-131. DOI: 10.3969/j.issn.1674-7445.2022.01.019.GAO WD, YANG LL, YIN QC. Research progress on the role of oxidative stress in ischemia-reperfusion injury of marginal donor liver transplantation[J]. Organ Transplant, 2022, 13(1): 126-131. DOI: 10.3969/j.issn.1674-7445.2022.01.019. [20] WU L, TIAN X, ZUO H, et al. miR-124-3p delivered by exosomes from heme oxygenase-1 modified bone marrow mesenchymal stem cells inhibits ferroptosis to attenuate ischemia-reperfusion injury in steatotic grafts[J]. J Nanobiotechnology, 2022, 20(1): 196. DOI: 10.1186/s12951-022-01407-8. [21] YANG B, DUAN W, WEI L, et al. Bone marrow mesenchymal stem cell-derived hepatocyte-like cell exosomes reduce hepatic ischemia/reperfusion injury by enhancing autophagy[J]. Stem Cells Dev, 2020, 29(6): 372-379. DOI: 10.1089/scd.2019.0194. [22] ZHANG Y, LI Y, WANG Q, et al. Attenuation of hepatic ischemia-reperfusion injury by adipose stem cell-derived exosome treatment via ERK1/2 and GSK-3β signaling pathways[J]. Int J Mol Med, 2022, 49(2): 13. DOI: 10.3892/ijmm.2021.5068. [23] PIAO C, ZHANG Q, XU J, et al. Optimal intervention time of ADSCs for hepatic ischemia-reperfusion combined with partial resection injury in rats[J]. Life Sci, 2021, 285: 119986. DOI: 10.1016/j.lfs.2021.119986. [24] ZHENG J, LU T, ZHOU C, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells protect liver ischemia/reperfusion injury by reducing CD154 expression on CD4+ T cells via CCT2[J]. Adv Sci (Weinh), 2020, 7(18): 1903746. DOI: 10.1002/advs.201903746. [25] SHI M, LIU Z, WANG Y, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection[J]. Stem Cells Transl Med, 2017, 6(12): 2053-2061. DOI: 10.1002/sctm.17-0134. [26] ZHANG Y, ZHANG J, YI H, et al. A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase Ⅰ/Ⅱ randomized, open-label, controlled trial[J]. Stem Cell Res Ther, 2021, 12(1): 244. DOI: 10.1186/s13287-021-02246-4. [27] LI J, PENG Q, YANG R, et al. Application of mesenchymal stem cells during machine perfusion: an emerging novel strategy for organ preservation[J]. Front Immunol, 2021, 12: 713920. DOI: 10.3389/fimmu.2021.713920. [28] UEMOTO S, FUJIMOTO Y, TERATANI T, et al. Introduction of mesenchymal stem cells for liver surgery (hepatectomy and transplantation)[M]// NAKAO K, MINATO N, UEMOTO S. Innovative medicine: basic research and development. Tokyo: Springer, 2015. [29] 王惠, 赵鹏翔, 张旭娟, 等. 间充质干细胞在疾病治疗中的应用潜力[J]. 生物技术进展, 2021, 11(6): 688-693. DOI: 10.19586/j.2095-2341.2021.0055.WANG H, ZHAO PX, ZHANG XJ, et al. The application potential of mesenchymal stem cells in the treatment of diseases[J]. Current Biotechnol, 2021, 11(6): 688-693. DOI: 10.19586/j.2095-2341.2021.0055. [30] WABITSCH S, BENZING C, KRENZIEN F, et al. Human stem cells promote liver regeneration after partial hepatectomy in Balb/c nude mice[J]. J Surg Res, 2019, 239: 191-200. DOI: 10.1016/j.jss.2019.02.010. [31] LIU T, MU H, SHEN Z, et al. Autologous adipose tissue-derived mesenchymal stem cells are involved in rat liver regeneration following repeat partial hepatectomy[J]. Mol Med Rep, 2016, 13(3): 2053-2059. DOI: 10.3892/mmr.2016.4768. [32] SONG XJ, ZHANG L, LI Q, et al. hUCB-MSC derived exosomal miR-124 promotes rat liver regeneration after partial hepatectomy via downregulating Foxg1[J]. Life Sci, 2021, 265: 118821. DOI: 10.1016/j.lfs.2020.118821. [33] WANG W, DU Z, YAN J, et al. Mesenchymal stem cells promote liver regeneration and prolong survival in small-for-size liver grafts: involvement of C-Jun N-terminal kinase, cyclin D1, and NF-κB[J]. PLoS One, 2014, 9(12): e112532. DOI: 10.1371/journal.pone.0112532. [34] HAZRATI A, MALEKPOUR K, SOUDI S, et al. Mesenchymal stromal/stem cells and their extracellular vesicles application in acute and chronic inflammatory liver diseases: emphasizing on the anti-fibrotic and immunomodulatory mechanisms[J]. Front Immunol, 2022, 13: 865888. DOI: 10.3389/fimmu.2022.865888. [35] PIAO C, SANG J, KOU Z, et al. Effects of exosomes derived from adipose-derived mesenchymal stem cells on pyroptosis and regeneration of injured liver[J]. Int J Mol Sci, 2022, 23(20): 12065. DOI: 10.3390/ijms232012065. [36] 谢炎, 蒋文涛. 供肝保存与功能维护助力肝移植发展[J]. 器官移植, 2023, 14(2): 201-206. DOI: 10.3969/j.issn.1674-7445.2023.02.004.XIE Y, JIANG WT. Liver graft preservation and functional maintenance accelerate the development of liver transplantation[J]. Organ Transplant, 2023, 14(2): 201-206. DOI: 10.3969/j.issn.1674-7445.2023.02.004. [37] 曹欢, 宋红丽, 沈中阳. 供肝体外保存技术的研究进展[J]. 中华肝胆外科杂志, 2020, 26(3): 229-233. DOI: 10.3760/cma.j.issn.1007-8118.2020.03.020.CAO H, SONG HL, SHEN ZY. Progress in research on donor liver preservation technology in vitro[J]. Chin J Hepatobiliary Surg, 2020, 26(3): 229-233. DOI: 10.3760/cma.j.issn.1007-8118.2020.03.020. [38] 刘子文, 王文波. 缺氧培养调控间充质干细胞的生理活性[J]. 中国组织工程研究, 2022, 26(13): 2127-2132. https://www.cnki.com.cn/Article/CJFDTOTAL-XDKF202213029.htmWANG ZW, WANG WB. Regulatory effects of hypoxic culture on physiological activities of mesenchymal stem cells[J]. Chin J Tissue Eng Res, 2022, 26(13): 2127-2132. https://www.cnki.com.cn/Article/CJFDTOTAL-XDKF202213029.htm [39] 王媞尔, 史明霞. 间充质干细胞旁分泌作用的研究进展[J]. 实用医学杂志, 2021, 37(13): 1651-1654. DOI: 10.3969/j.issn.1006-5725.2021.13.001.WANG TR, SHI MX. Research advance in paracrine role of mesenchymal stem cells[J]. J Pract Med, 2021, 37(13): 1651-1654. DOI: 10.3969/j.issn.1006-5725.2021.13.001. [40] YANG Y, LEE EH, YANG Z. Hypoxia-conditioned mesenchymal stem cells in tissue regeneration application[J]. Tissue Eng Part B Rev, 2022, 28(5): 966-977. DOI: 10.1089/ten.TEB.2021.0145. [41] 白佳萌, 刘光伟, 谢露, 等. 间充质干细胞及其外泌体在肝再生领域的应用[J]. 中国组织工程研究, 2022, 26(19): 3071-3077. https://www.cnki.com.cn/Article/CJFDTOTAL-XDKF202219022.htmBAI JM, LIU GW, XIE L, et al. Application of mesenchymal stem cells and exosomes in liver regeneration[J]. Chin J Tissue Eng Res, 2022, 26(19): 3071-3077. https://www.cnki.com.cn/Article/CJFDTOTAL-XDKF202219022.htm [42] NGO ATL, LE HM, TRINH NTH, et al. Clinically relevant preservation conditions for mesenchymal stem/stromal cells derived from perinatal and adult tissue sources[J]. J Cell Mol Med, 2021, 25(22): 10747-10760. DOI: 10.1111/jcmm.17016. [43] DETRY O, VANDERMEULEN M, DELBOUILLE MH, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase Ⅰ-Ⅱ, open-label, clinical study[J]. J Hepatol, 2017, 67(1): 47-55. DOI: 10.1016/j.jhep.2017.03.001. [44] CASIRAGHI F, PERICO N, PODESTÀ MA, et al. Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: a randomized controlled trial[J]. Am J Transplant, 2021, 21(8): 2795-2809. DOI: 10.1111/ajt.16468. -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 189
- HTML全文浏览量: 36
- PDF下载量: 41
- 被引次数: 0
